Analytical Method Validation and Quantitative Analysis for Active Pharmaceutical Ingredient and Marketed Formulation of Teneligliptin Hydrobromide by UV Spectroscopy

Abstract

A Dipeptidyl peptidase-4 inhibitor teneligliptin hydrobromide is used for lowering blood glucose levels in people with diabetes mellitus. A very straight forward, quick, responsive and accurate UV- Spectrophotometric method of analysis have been developed for assessment of Teneligliptin Hydrobromide in pharmaceutical formulation. Since teneligliptin hydrobromide only absorbs UV in the low wavelength area, it cannot be identify with high sensitivity. Teneligliptin Hydrobromide has shown successful results for various analytical instruments only in the permutation of Taurine and Sodium periodate. The API was derivatives using Taurine and Sodium periodate in water and methanol. Drug exhibited distinct λmax in methanol at 281nm. Linearity was observed in the concentration range 10-80 μg/ml. The method was validated by recovery studies. The methods used are inexpensive and sensitive for the inference of teneligliptin hydrobromide in bulk drug and tablet dosage forms.